Nordwand Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.8M Sell
11,794
-205
-2% -$208K 1.9% 15
2025
Q4
$12.9M Buy
11,999
+20
+0.2% +$19.1K 2.25% 9
2025
Q3
$9.14M Buy
11,979
+1,031
+9% +$767K 1.45% 17
2025
Q2
$8.53M Buy
+10,948
New +$8.51M 1.34% 16

Other funds holding LLY

Nordwand Advisors's LLY Position: Q1 2026 in Review

Nordwand Advisors reduced its Eli Lilly (LLY) stake by 1.7% in Q1 2026, selling an estimated $208K and leaving 11,794 shares worth $10.8M. The position accounts for 1.9% of the portfolio, ranked #15.

Nordwand Advisors first reported a position in LLY in Q2 2025 and has held it in 4 quarters since. The position peaked at $12.9M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Nordwand Advisors held 11,794 shares of Eli Lilly worth $10.8M as of Q1 2026.
  • Nordwand Advisors sold 205 Eli Lilly shares in Q1 2026, an estimated $208K.
  • Eli Lilly made up 1.9% of Nordwand Advisors's portfolio in Q1 2026, its #15 holding.
  • Nordwand Advisors first reported a position in Eli Lilly in Q2 2025 and has held it in 4 quarters since.
  • Nordwand Advisors's Eli Lilly position peaked at $12.9M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Nordwand Advisors's 13F filing for Q1 2026, filed 7 May 2026.